Orlando
,
USA
7 - 9 December 2025
67th Annual Meeting of the American Society of Hematology (ASH 2025)
Presentation schedule and materials
Saturday, 06 December 2025
17:30
- 19:30
ET
2669
POSTER
Trust and Relationships between People with Sickle Cell Disease and Healthcare Professionals: Regional comparisons from the LISTEN Survey
Biree Andemariam1, Shashidhar Rao2, Rohan Kolla3, Emma Tan2, Johnny Mahlangu4
MATERIALS AVAILABLE
17:30
- 19:30
ET
1158
POSTER
Smartphone app for noninvasive, at-home pediatric hemoglobin monitoring in sickle cell disease.
Rob Mannino1, Kunjan Rana2, Wilbur Lam1, Inga Hegemann3, Psalm Inusa2, Janne Madsen3, Erika Tyburski1
MATERIALS AVAILABLE
17:30
- 19:30
ET
1288
POSTER
Concizumab Efficacy in Patients With Hemophilia A/B Without Inhibitors from the Phase 3 explorer8 Study: A Post-hoc Sensitivity Analysis for the Intra-patient Comparison of Concizumab With Previous Prophylaxis
Anthony KC Chan1, Hermann Eichler2, Julien Bovet3, Renée Brown Frandsen3, Allison P Wheeler4, Pratima Chowdary5
MATERIALS AVAILABLE
Sunday, 07 December 2025
12:30
- 12:45
ET
537
ORAL PRESENTATION
Mim8 prophylaxis in adults and adolescents with Hemophilia A: 52-week efficacy and safety outcomes from the Phase 3 FRONTIER2 study
Steven Lentz1, Aby Abraham2, Cihan Ay3, Anthony Chan4, Víctor Jiménez-Yuste5, Johannes Oldenburg6, Maria Elisa Mancuso7, 8, Johnny Mahlangu9, Tadashi Matsushita10, Lize van Vulpen11, Renchi Yang12, Amalie Rhode Høgh Nielsen13, Ilgiz Rakhmatullin13, Pratima Chowdary14
MATERIALS AVAILABLE
13:15
- 13:30
ET
540
ORAL PRESENTATION
From efficacy to experience: 52-week patient-reported outcomes with Mim8 in adolescents and adults with Hemophilia A with or without inhibitors (FRONTIER2)
Cedric Hermans1, Sanjay Ahuja2, Hazza Alzahrani3, Cihan Ay4, Peter Kampmann5, Samya Obaji6, Sophie Susen7, Ciprian Tomuleasa8, Lize van Vulpen9, Amalie Rhode Høgh Nielsen10, Ilgiz Rakhmatullin10, Carmen Escuriola-Ettingshausen11
MATERIALS AVAILABLE
17:45
- 18:00
ET
618
ORAL PRESENTATION
Etavopivat in Adolescents with Sickle Cell Disease: Emerging Safety and Efficacy Findings from the First Cohort of the Ongoing Phase 1/2 HIBISCUS Kids Study
Adlette Inati1, Bernhards Ogutu2,3, E. Leila Jerome Clay4, Pavithra Dhayakar5, Kaming Lo6, Miguel Abboud7
MATERIALS AVAILABLE
18:00
- 20:00
ET
3070
POSTER
Concizumab Plasma Concentration Measurements for Personalized Dose Adjustment in Patients with Hemophilia A/B with and without Inhibitors: Data from the Phase 3 explorer7 and explorer8 Studies
Hermann Eichler1, Chris Barnes2, Johnny Mahlangu3, Mary Mathias4, Jakob Oemar Gjørret5, Thomas Porstmann6, Tulika Seth7, Sonata Šaulytė Trakymienė8
MATERIALS AVAILABLE
18:00
- 20:00
ET
2976
POSTER
HIBISCUS 2 (Trial-in-Progress): A Global, Phase 3, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults with Sickle Cell Disease
Pavithra Dhayakar1, Eric Wu2
MATERIALS AVAILABLE
18:00
- 20:00
ET
2952
POSTER
Bridging the Gap: Global Caregiver Perspectives on Awareness, Motivators, and Barriers to Clinical Trial Participation in Sickle Cell Disease
John James1, Johnny Mahlangu2, Raffaella Colombatti3, Cassandra Trimnell4, Darren Fleetwood5, Emma Tan6, Biree Andemariam7
MATERIALS AVAILABLE
Monday, 08 December 2025
18:00
- 20:00
ET
6222
POSTER
Stability and Evolution of Individual-Level Biomarker Patterns Across Repeated Vaso-Occlusive Crises in Sickle Cell Disease
Kim Summers1, Alfonso Portabales1, Orlando Agrippa1, Kunjan D. Rana2, Paul Telfer3, Sanne Lugthart4
MATERIALS AVAILABLE
18:00
- 20:00
ET
4737
POSTER
Modified-Release Formulation of Decitabine and Tetrahydrouridine Combination Not Only Increases Exposure to Decitabine but Reduces Exposure to Unfavorable Decitabine Metabolites in Healthy Volunteers
Helene Hausner1, Hanne Kjær Offenberg1, Marie Aavang Geist1, Samar Al-Behaisi2, Hans Helleberg1
MATERIALS AVAILABLE
18:00
- 20:00
ET
4848
POSTER
Immunogenicity Assessment of Concizumab in Patients with Hemophilia A and B: Assays Developed to Measure Anti-Drug Antibodies and Integrated Results from Clinical Trials
Luis Carlos Pérez Tosar1, Thomas Porstmann2, Lone Hummelshøj Landsy1
MATERIALS AVAILABLE
18:00
- 20:00
ET
4830
POSTER
Mim8 improves the In Vivo hemostasis of select hemophilia B causing factor IX variants
Sebastian Leyes Porello1, Kyumin Lee1, Julia Chau1, Lacramioara Ivanciu1, 2, Shelley Nakaya Fletcher3, Jill Johnsen4, Jacob Lund5, Ben Samelson-Jones1, 2
MATERIALS AVAILABLE
Keywords